Literature DB >> 17138135

Molecular markers of prostate cancer.

Timothy J Bradford1, Scott A Tomlins, Xiaoju Wang, Arul M Chinnaiyan.   

Abstract

Although prostate-specific antigen (PSA) has evolved as a very useful tool for detection of prostate cancer, there remains an urgent need for more accurate biomarkers to diagnose prostate cancer and predict cancer-related outcomes. Recent advances in the study of proteomics and high throughput techniques have led to the discovery of many potential biomarkers for prostate cancer. This article briefly reviews the current status of PSA testing and discusses several candidate protein biomarkers for prostate cancer, as well as highlighting some recent proteomic discoveries with the potential to supplement or even replace PSA for the diagnosis and prognosis of prostate cancer.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17138135     DOI： 10.1016/j.urolonc.2006.07.004

Source DB:  PubMed          Journal:  Urol Oncol        ISSN： 1078-1439            Impact factor:   3.498


  20 in total

1.  Computational prediction of human proteins that can be secreted into the bloodstream.

Authors:  Juan Cui; Qi Liu; David Puett; Ying Xu
Journal:  Bioinformatics       Date:  2008-08-12       Impact factor: 6.937

2.  Emergence of ETS transcription factors as diagnostic tools and therapeutic targets in prostate cancer.

Authors:  Said Rahim; Aykut Uren
Journal:  Am J Transl Res       Date:  2013-04-19       Impact factor: 4.060

3.  Lacrimal Glands May Represent Organs at Risk for Radionuclide Therapy of Prostate Cancer with [(177)Lu]DKFZ-PSMA-617.

Authors:  Melanie Hohberg; Wolfgang Eschner; Matthias Schmidt; Markus Dietlein; Carsten Kobe; Thomas Fischer; Alexander Drzezga; Markus Wild
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

4.  Protein expression profiles distinguish between experimental invasive pulmonary aspergillosis and Pseudomonas pneumonia.

Authors:  Denise A Gonzales; Carlos De Torre; Honghui Wang; Christopher B Devor; Peter J Munson; Sai-Xia Ying; Steven J Kern; Ruta Petraitiene; David L Levens; Thomas J Walsh; Anthony F Suffredini
Journal:  Proteomics       Date:  2010-12       Impact factor: 3.984

5.  The pathogenesis of prostate cancer: from molecular to metabolic alterations.

Authors:  Elisa Benedettini; Paul Nguyen; Massimo Loda
Journal:  Diagn Histopathol (Oxf)       Date:  2008-05

6.  Identification and characterization of small-molecule inhibitors of hepsin.

Authors:  John R Chevillet; Gemma J Park; Antonio Bedalov; Julian A Simon; Valeri I Vasioukhin
Journal:  Mol Cancer Ther       Date:  2008-10       Impact factor: 6.261

Review 7.  Translating insights from the cancer genome into clinical practice.

Authors:  Lynda Chin; Joe W Gray
Journal:  Nature       Date:  2008-04-03       Impact factor: 49.962

8.  PSMA-targeted SPECT agents: mode of binding effect on in vitro performance.

Authors:  Jessie R Nedrow-Byers; Adam L Moore; Tanushree Ganguly; Mark R Hopkins; Melody D Fulton; Paul D Benny; Clifford E Berkman
Journal:  Prostate       Date:  2012-08-21       Impact factor: 4.104

9.  CD24 is an effector of HIF-1-driven primary tumor growth and metastasis.

Authors:  Shibu Thomas; Michael A Harding; Steven C Smith; Jonathan B Overdevest; Matthew D Nitz; Henry F Frierson; Scott A Tomlins; Glen Kristiansen; Dan Theodorescu
Journal:  Cancer Res       Date:  2012-08-27       Impact factor: 12.701

10.  Targeting PSMA with a Cu-64 Labeled Phosphoramidate Inhibitor for PET/CT Imaging of Variant PSMA-Expressing Xenografts in Mouse Models of Prostate Cancer.

Authors:  Jessie R Nedrow; Joseph D Latoche; Kathryn E Day; Jalpa Modi; Tanushree Ganguly; Dexing Zeng; Brenda F Kurland; Clifford E Berkman; Carolyn J Anderson
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.